Nautilus Biotechnology

NAUT · NASDAQ

$2.55−$0.08 (−3.04%)TodayMarket closed · Oct 20, 7:57 PM ET

Prev close $2.63

About NAUT

Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 127 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprises the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs. Its platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells.

Employees: 127
Headquarters: Seattle, Washington
Listed: Aug 7, 2020
Sector: Health Care
Industry: Life Sciences Tools & Services
Website: nautilus.bio

NAUT key statistics

Market cap: 324.50M
Price-earnings ratio: 0.00
Dividend yield: —
Average volume: 9.90M
Volume: 10.02M
Open price: $2.53
High today: $2.71
Low today: $2.38
52 Week high: $4.31
52 Week low: $0.8411

Nautilus Biotechnology (NAUT) at a glance

As of Oct 20, 2026, Nautilus Biotechnology (NAUT) shares are priced at $2.55, giving the company a market cap of 324.50M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.38 and $2.71. The current price is 7.1% above the day's low and 5.9% below its high.

Volume so far is 10.02M shares, in line with the average of 9.90M shares a day.

Over the past year Nautilus Biotechnology has ranged from $0.8411 to $4.31, and now sits 49% of the way up that range.

Nautilus Biotechnology met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.11 per share against an estimate of -$0.1377.

The average analyst price target is $3.91, 53.3% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy

Buy100.0%
Hold0.0%
Sell0.0%

Price target · 5 analystsAvg $3.91

Low: $3.54
Now: $2.55
High: $4.20

NAUT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 20.7% on average.

NAUT news

Jul 28, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Apr 28, 9:20 AM ET
Nautilus Biotechnology Reports Q1 2026 Results: Full Earnings Call Transcript
Feb 26, 12:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session

Similar companies

Companies in the same industry as Nautilus Biotechnology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.